Health E Circuits

Study

Predicting Risk for Metabolic Syndrome (MetSyn) (2014-2015)

​

Objective

Study was conducted to determine the ability of the BEST scan to detect presence or absence of Metabolic Syndrome as diagnosed and determined by the NCEP/APTIII criteria.

​

Design

Prospective, single-center, non-randomized feasibility study trial of 193 patients who met eligibility criteria. Men and women aged 21-85 who were free of or not on any treatment for cancer, renal failure, autoimmune disorders, and MS were enrolled.

​

Results

Demonstrated safety and effectiveness. The BEST scan had a statistically significant correlation with Metabolic Syndrome as demonstrated by medical diagnosis (AUC = .97)